The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro.
about
Epigenetic control of HIV-1 post integration latency: implications for therapyImpact of Chromatin on HIV ReplicationThe macrophage: a therapeutic target in HIV-1 infectionDevelopments in HIV-1 immunotherapy and therapeutic vaccination.Eradication therapies for HIV Infection: time to begin again.Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells.Combination of biological screening in a cellular model of viral latency and virtual screening identifies novel compounds that reactivate HIV-1Provirus activation plus CD59 blockage triggers antibody-dependent complement-mediated lysis of latently HIV-1-infected cells.Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected indian rhesus macaques.Histone deacetylase inhibitors and HIV latency.Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.Gene silencing in HIV-1 latency by polycomb repressive group.Specific inhibition of histone deacetylase 8 reduces gene expression and production of proinflammatory cytokines in vitro and in vivoHistone deacetylase inhibitors for treating a spectrum of diseases not related to cancerHistone deacetylase inhibitors for purging HIV-1 from the latent reservoir.Targeting inflammation in heart failure with histone deacetylase inhibitors.The oral histone deacetylase inhibitor ITF2357 reduces cytokines and protects islet β cells in vivo and in vitro.Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study.H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells.Sequential treatment with 5-aza-2'-deoxycytidine and deacetylase inhibitors reactivates HIV-1.Targeting HIV latency: pharmacologic strategies toward eradication.HIV-1 transcription and latency: an update.Altering cell death pathways as an approach to cure HIV infection.Opportunities to exploit non-neutralizing HIV-specific antibody activity.Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors.Class I and II histone deacetylase inhibition by ITF2357 reduces SLE pathogenesis in vivo.Histone deacetylase inhibitors as therapeutic agents for acute central nervous system injuries.Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus.HDAC inhibitors in HIV.HIV reservoirs and strategies for eradication.Reactivation of latent HIV by histone deacetylase inhibitors.Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials.Reactivation of latent HIV: do all roads go through P-TEFb?HIV-1 latency: an update of molecular mechanisms and therapeutic strategies.The acetyl code in rheumatoid arthritis and other rheumatic diseases.Dilazep synergistically reactivates latent HIV-1 in latently infected cells.Genetic and Epigenetic Regulation of CCR5 Transcription.Lysine deacetylases are produced in pancreatic beta cells and are differentially regulated by proinflammatory cytokines.Epigenetic Metabolite Acetate Inhibits Class I/II Histone Deacetylases, Promotes Histone Acetylation, and Increases HIV-1 Integration in CD4+ T Cells.Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation.
P2860
Q26781191-4AF6158C-6830-4793-BE4B-68E039C8323FQ26782046-B13C7A63-AEAD-43A7-9850-ABD2D9AD845CQ26823236-40E04667-43F0-4D1E-A539-AC7F5EDB9E81Q30364312-68920FF5-6CFB-4CED-A884-944E9593AA6FQ30399588-64A86563-5E65-49F7-8152-85490C334D69Q33838633-C3BF3D7C-4660-4BFE-9B7B-9D5FBD8B2605Q34132738-5AEFE102-FDDE-4F64-B7E5-C4E9E7E93F33Q34218827-4F48E4D6-4343-45AC-B31C-B5FD0C35F38EQ34596417-9927E62D-7054-4176-8975-13ACB2617CC0Q34816844-C0BFB5F0-07D0-40E8-B1C8-01AFE49B11E3Q34869927-3C6A7618-8117-4849-BD12-8B61EFA904C0Q34980577-31C82A4C-852E-4102-A6B2-ED8FEE346F2FQ35002986-A7BF4922-EC7C-441F-A5AB-80F7F0B6E4C1Q35016934-474A0A2C-D95D-4F48-9F27-971F22E10E1BQ35016964-A656B9FB-95B5-404E-9C61-7D0B94FE482EQ35016989-6D46CE28-E147-4BAD-A813-A98486179609Q35017018-B71FB93B-BCEB-4440-B0F2-33F9C8BA6945Q35057326-7140EA2B-F574-4445-B5B0-D601F0F42FECQ35914266-DDE122AA-EBB5-49E2-A72F-DBE93A37BE88Q36525896-617FE40D-172E-464A-A7D8-FDCD78F711A1Q36901950-4606B424-D958-4C28-AB4F-A0407EFDFA23Q36976156-DC2E109A-5A92-4C3A-980A-72F34AB5E1C5Q37062057-C2959666-D618-4D2C-86E4-96878D4C4681Q37113941-D7E10B07-6747-4D11-8D8A-77B3A7B56D10Q37626634-7C7A5D2C-7904-4A0D-8E56-89896F86CD38Q37657613-D528CC4B-DE5A-4D34-8D91-0A02A98136D6Q37832963-A11AA2FB-20B3-4B76-B621-AB5A85751401Q37832964-8F99579D-3E88-4E4E-93D4-47D853329397Q37956178-94BD6BBE-E09E-422C-BE18-5403BBDA65E0Q37976293-00E920FC-FA2B-45D9-8A6F-2799F8CC9120Q38091753-B6A152EF-8E79-4D03-B121-A6EB5F7EDF43Q38096822-96455FC7-1CC5-4738-828B-85EF3E9C3630Q38177273-01AA6D85-3B71-45B0-8331-B1EC928382FEQ38204866-FA3FE695-6979-4312-A0F4-AE067191667AQ39094945-932C5789-5589-4256-A074-E37135C3D82FQ39148809-40C5B4E6-4A0C-47B9-B341-69B7DAA233A4Q39216552-69B69D81-5CAA-4F06-9228-434B6B862A0BQ39650299-EA47BA07-3827-47E8-B71F-ED21F17CC340Q40187559-B389960E-BF92-4984-99E8-8DB382891B96Q41885967-44F09913-397A-4ED9-A278-D998117394EC
P2860
The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
The histone deacetylase inhibi ...... ent HIV-1 expression in vitro.
@ast
The histone deacetylase inhibi ...... ent HIV-1 expression in vitro.
@en
type
label
The histone deacetylase inhibi ...... ent HIV-1 expression in vitro.
@ast
The histone deacetylase inhibi ...... ent HIV-1 expression in vitro.
@en
prefLabel
The histone deacetylase inhibi ...... ent HIV-1 expression in vitro.
@ast
The histone deacetylase inhibi ...... ent HIV-1 expression in vitro.
@en
P2093
P2860
P1476
The histone deacetylase inhibi ...... ent HIV-1 expression in vitro.
@en
P2093
Antonio Furlan
Brent E Palmer
Gianluca Fossati
Marcel F Nold
Paolo Mascagni
Shay Matalon
P2860
P356
10.1097/QAI.0B013E3181D3DCA3
P407
P577
2010-05-01T00:00:00Z